Suzman, D. L., Agrawal, S., Ning, Y., Maher, V. E., Fernandes, L. L., Karuri, S., . . . Beaver, J. A. (2018). FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin‐Containing Chemotherapy. Oncologist.
Citación estilo ChicagoSuzman, Daniel L., et al. "FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients With Advanced Urothelial Carcinoma Ineligible for Cisplatin‐Containing Chemotherapy." Oncologist 2018.
Cita MLASuzman, Daniel L., et al. "FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients With Advanced Urothelial Carcinoma Ineligible for Cisplatin‐Containing Chemotherapy." Oncologist 2018.